Ascorbic acid in cancer chemoprevention: Translational perspectives and efficacy

Current Drug Targets

Volumn 13, Issue 14, 2012, Pages 1757-1771

  Ullah, Mohammad F ^a   Bhat, Showket H ^a   Hussain, Eram ^a   Abu Duhier, Faisel ^a   Ahmad, Aamir ^b   Hadi, S M ^c  

^a UNIVERSITY OF TABUK   (Saudi Arabia)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Ascorbic acid; Chemoprevention; Phytochemicals

Indexed keywords

ALPHA TOCOPHEROL; ARSENIC TRIOXIDE; ASCORBIC ACID; ASPARAGINASE; BLEOMYCIN; BORTEZOMIB; CISPLATIN; CREATINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERLOTINIB; ETHYLNITROSOUREA; FLUOROURACIL; GEMCITABINE; MELPHALAN; METHOTREXATE; METHYLGLYOXAL; PACLITAXEL; PLACEBO; PROCARBAZINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VINBLASTINE; VINCRISTINE;

ADJUVANT THERAPY; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCORBIC ACID DEFICIENCY; ASCORBIC ACID METABOLISM; BIOAVAILABILITY; BIOSYNTHESIS; BREAST CANCER; CANCER CELL; CELL COMMUNICATION; CELL SURVIVAL; CHEMOPROPHYLAXIS; COLORECTAL CANCER; CYTOTOXICITY; DNA CLEAVAGE; DNA DAMAGE; DNA REPAIR; DRUG COMPETITION; DRUG EFFICACY; DRUG MEGADOSE; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; KIDNEY CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SCURVY; SINGLE DRUG DOSE; STEADY STATE; TARGET CELL; TRANSLATIONAL RESEARCH; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ASCORBIC ACID; CHEMOPREVENTION; FRUIT; HUMANS; NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME; VEGETABLES;

EID: 84879307951     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012804545669     Document Type: Article

References (172)

1. World Health Organization. Cancer fact sheet. February 2011. Accessed March 30, 2012. http://www.who.int/mediacentre/fact sheets/fs297/en/ index.html.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
3. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981; 66: 1191-1308.
4. Michels KB, Givannucci E, Joshipura KJ, et al. Prospective study of fruit and vegetable consumption and incidence of colon and rectal cancers. J Natl Cancer Inst 2000; 92: 1740-1752.
5. Levine M, Rumsey SC, Daruwala R, Park JB, Wang Y. Criteria and recommendations for vitamin C intake. JAMA 1999; 281: 1415-1423.
6. Tuyns A. Protective effect of citrus fruit on esophageal cancer. Nutr Cancer 1983; 5: 195-200.
7. Tuyns A, Riboli F, Doornbos G, Pequignot G. Diet and esophageal cancer in Calvados (France). Nutr Cancer 1987; 9: 81-92.
8. Creagen ET, Moertal CG, O'Fallon JR, et al. Failure of high-dose Vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer: a controlled trial. New England J Med 1979; 301: 687-690.
9. Moertal CG, Fleming TR, Creagen ET, Rubin AJ, O'Connell MJ, Ames MM. High-dose Vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy: a randomized double blind comparison. New England J Med 1985; 312: 137-141
10. Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, Wesley RA, Levine M. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 2004; 140: 533-537.
11. Lind J. A treatise of the scurvy. Edinburgh: Sands, Murray and Cochrane, 1753. Reprinted. C. P. Stewart and D. Guthrie (eds.). Edinburgh: Edinburgh University Press, 1953.
12. Szent-GyOrgyi, A. Observations of the functions of peroxidase systems and the chemistry of the adrenal cortex. Biochem J 1928; 22: 1387-1409.
13. Cameron E, Pauling L. Cancer and Vitamin C. New York, NY: W.W. Norton & Company, Inc.; 1979: 101.
14. McCormick WJ. Cancer: the preconditioning factor in pathogenesis. Arch Pediatr 1954; 71: 313-322.
15. McCormick WJ. Cancer: a collagen disease, secondary to a nutritional deficiency? Arch Pediatr 1959; 76: 166-171.
16. Ewan Cameron, Linus Pauling and Brian Leibovitz. Ascorbic Acid and Cancer: A Review. Cancer Res 1979; 39: 663-681.
17. Gladiis Block. Vitamin C and cancer prevention: the epidemiologic evidence. Am J Clin Nutr 1991; 53: 270S-82S.
18. Kathleen A. Head. Ascorbic Acid in the Prevention and Treatment of Cancer. Altern Med Rev 1998; 3(3): 174-186
19. Khaw KT, Bingham S, Welch A. Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study. Lancet 2001; 357: 657-663.
20. Schorah CJ, Sobala M, Collis N, Primrose JN. Gastric juice ascorbic acid: effects of disease and implications for gastric carcinogenesis. Am J Clin Nutr 1991; 53: 287S-293S.
21. Sobala GM, Pignaetelli B, Schorah CJ, et al. Levels of nitrite, nitrate, N-nitroso compounds, ascorbic acid in gastric juice of patients with and without precancerous conditions of the stomach. Carcinogenesis 1991; 12: 193-18.
22. Drake IM, Davies MJ, Mapstone NP, et al. Ascorbic acid may protect against human gastric cancer by scavenging mucosal oxygen radicals. Carcinogenesis 1996; 17: 559-562.
23. Cohen M, Bhagavan HN. Ascorbic acid and gastrointestinal cancer. J Am Coll Nutr 1995; 14: 565-578.
24. Howe GR, Burch JD. Nutrition and pancreatic cancer. Cancer Causes Control 1996; 7: 69-82.
25. Mettlin C, Graham S, Priore R, et al. Diet and cancer of the esophagus. Nutr Cancer 1981; 2: 143-147.
26. Greco AM, Gentile M, Di Filippo O, Coppola A. Study of blood vitamin C in lung and bladder cancer patients before and after treatment with ascorbic acid. A preliminary report. Acta Vitaminol Enzymol 1982; 4: 155-162.
27. Potter JD, McMichael AJ. Diet and cancer of the colon and rectum: A case-control study. J Natl Cancer Inst 1986; 76: 557-569.
28. Bussey HJ, DeCosse JJ, Deschner EE, et al. A randomized trial of ascorbic acid in polyposis coli. Cancer Am J Epidemiol 1982; 50: 1434-149.
29. Herrero R, Potischman N, Brinton L, et al. A case-control study of nutrient status and invasive cervical cancer. Am J Epidemiol 1991; 134: 1347-1355.
30. VanEenwyk J, Davis FG, Colman N. Folate, vitamin C and cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev 1992; 1: 119-124.
31. Liu T, Soong SJ, Wilson NP, et al. A case control study of nutritional factors and cervical dysplasia. Cancer Epidemiol Biomarkers Prev 1993; 2: 525-530.
32. Nunez MC, Ortiz de Apodaca y Ruiz A. Ascorbic acid in the plasma and blood cells of women with breast cancer. The effect of the consumption of food with an elevated content of this vitamin. Nutr Hosp 1995; 10: 368-372.
33. Kushi LH, Fee RM, Sellers TA, et al. Intake of vitamins A, C and E and postmenopausal breast cancer. The Iowa Women's Health Study. Am J Epidemiol 1996; 144: 165-174.
34. Valente A, Albuquerque TG, Sanches-Silva A, Costa HS. Ascorbic acid content in exotic fruits: A contribution; to produce quality data for food composition databases. Food Res Internat 2011; 44: 2237-2242.
35. Davey MW, Montagu MV, Inzé D, Sanmartin M, Kanellis A, Smirnoff N et al. Plant L-ascorbic acid: chemistry, function, metabolism, bioavailability and effects of processing. J Sci Food Agric 2000; 80: 825-860.
36. Smirnoff N, Gatzek S. Ascorbate biosynthesis: A diversity of pathways. In Vitamin C. Function and Biochemistry in Animals and Plants, (H. Asard, J. M. May and N. Smirnoff, eds.), Bios Scientific Publishers, Oxford 2004 pp. 7-29.
37. Wheeler GL, Jones MA, Smirnoff N. The biosynthetic pathway of vitamin C in higher plants. Nature 1998; 393: 365-369.
38. Smirnoff N, Conklin PL, Loewus FA. Biosynthesis of ascorbic acid in plants: A renaissance. Annual Rev Plant Physiol Plant Mol Biol 2001; 52: 437-467.
39. Sauberlich HE, Bioavailability of vitamins. Prog Food Nutr Sci 1985; 9: 1-33.
40. Lewin S. "Vitamin C: Its Molecular Biology and Medical Potential." London: Academic Press, 1976.
41. Frei B, Traber M. The new US dietary reference for vitamins C and E. Redox Rep 2001; 6: 5-9
42. Levine M, Conry-Cantilena C, Wang Y, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 1996; 93: 3704-3709.
43. Levine M, Wang Y, Padayatty S, Morrow J. A new recommended dietary allowance of vitamin C for healthy young women. Proc Natl Acad Sci USA 2001; 98: 9842-9846.
44. Graumlich JF, Ludden TM, Conry-Cantilena C, Cantilena Jr LR, Wang Y, Levine M. Pharmacokinetic model of ascorbic acid in healthy male volunteers during depletion and repletion. Pharm Res 1997; 14: 1133-1139.
45. Agus D, Gambhir S, Pardridge W, Spielholz C, Baselga J, Vera J, et al. Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J Clin Invest 1997; 100: 2842-2848.
46. Vera J, Rivas C, Fischbarg J, Golde D. Mammalian facilitative hexose transporters mediate the transport of dehydroascorbic acid. Nature 1993; 364: 79-82.
47. Takanaga H, Mackenzie B, Hediger M. Sodium-dependent ascorbic acid transporter family SLC23. Pflugers Arch 2004; 447: 677-682.
48. Montel-Hagen A, Kinet S, Manel N, et al. Erythrocyte Glut1 triggers dehydroascorbic acid uptake in mammals unable to synthesize vitamin C. Cell 2008; 132: 1039-1048.
49. Omaya TS, Scala JH, Jacob RA Plasma ascorbic acid in adult males: effects of depletions and supplementation. J Am Coll Nutr 1986; 44: 257-264.
50. World Cancer Research Fund American Institute for Cancer Research, Food, nutrition and the prevention of cancer: a global perspective. WCRF, AICR,Washington, DC; 2007.
51. Cross CE, Halliwell B, Borish ET, Pryor WA, Ames BN, Saul RL et al. Oxygen radicals and human disease. Ann Intern Med 1987;107: 526-545.
52. Kovacic P, Jacintho JD. Mechanisms of carcinogenesis: focus on oxidative stress and electron transfer. Curr Med Chem2001; 8: 773-796.
53. Levin M. New concepts in the biology and biochemistry of ascorbic acid. New Engl J Med 1986; 31: 892-902.
54. Buettner GR, Jurkiewicz BA. Catalytic metals, ascorbate and free radicals: combinations to avoid. Radiat Res 1996; 145: 532-541.
55. Buettner GR, Moseley PL. EPR spin trapping of free radicals produced by bleomycin and ascorbate. Free Radic Res Commun 1993; 19: S89-S93.
56. Buettner GR. The pecking order of free radicals and antioxidants: lipid peroxidation, a-tocopherol, and ascorbate. Arch Biochem Biophys 1993; 300: 535-543.
57. Padayatty SJ, Katz A, Wang Y, et al. Vitamin C as an Antioxidant: Evaluation of Its Role in Disease Prevention. J Am Coll Nutr 2003; 22: 18-35
58. Dizdaroglu M, Jaruga P, Birincioglu M, Rodriguez H. Free radicalinduced damage to DNA: mechanisms and measurement, Free Rad Biol Med 2002; 32: 1102-1115.
59. Luperchio S, Tamir S, Tannenbaum SR. NO-induced oxidative stress and glutathione metabolism in rodent and human cells. Free Radic Biol Med 1996; 21: 513-59.
60. Odin AP. Vitamins as antimutagens: advantages and some possible mechanisms of antimutagenic action. Mutat Res 1997; 386: 39-67.
61. Carr AC, Frei B. Does vitamin C act as pro-oxidant under physiological conditions? FASEB J 1999; 13: 1007-1024.
62. Halliwell B. Vitamin C: antioxidant or pro-oxidant in vivo? Free Rad Res 1996; 25: 439-454.
63. Chesney JA, Mahoney JR, Eaton JW. A spectrophotometric assay for chlorine-containing compounds. Anal. Biochem 1991; 196: 262-266.
64. Menzel DB. Oxidation of biologically active reducing substances by ozone. Arch Environ Health 1971; 23: 149-153.
65. Chou PT, Khan AU. L-Ascorbic acid quenching of singlet delta molecular oxygen in aqueous media: generalized antioxidant property of vitamin C. Biochem Biophys Res Commun 1983; 115: 932-97.
66. Cooney RV, Ross PD, Bartolini GL. N-nitrosation and N-nitration of morpholine by nitrogen dioxide: inhibition by ascorbate, glutathione and α-tocopherol. Cancer Lett 1986; 32: 83-90.
67. Licht WR, Tannenbaum SR, Deen WM. Use of ascorbic acid to inhibit nitrosation: kinetic and mass transfer considerations for an in vitro system. Carcinogenesis 1988; 9: 365-372.
68. Kveder M, Pifat G, Pecar S, Schara M, Ramos, P, Esterbauer H. Nitroxide reduction with ascorbic acid in spin labeled human plasma LDL and VLDL. Chem Phys Lipids 1997; 85: 1-12
69. Bartlett D, Church DF, Bounds PL, Koppenol WH. The kinetics of the oxidation of L-ascorbic acid by peroxynitrite. Free Rad Biol Med 1995; 18: 85-92.
70. Edge R, Truscott TG. Prooxidant and antioxidant reaction mechanisms of carotene and radical interactions with vitamins E and C. Nutrition 1997; 13: 992-994.
71. Schumacker PT. Reactive oxygen species in cancer cells: Live by the sword, die by the sword. Cancer Cell 2006; 10: 175-176.
72. Devi GS, Prasad MH, Saraswathi I, Rao DN, Reddy PP. Free radicals, antioxidant enzymes and lipid peroxidation in different types of leukemia. Clin Chim Acta 2000; 293: 53-62.
73. Gupte A, Mumper RG. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev 2008; 35: 32-46.
74. Kong Q, Beel JA, Lillehei KO. A threshold concept for cancer therapy. Med Hypothesis 2000; 55: 29-35.
75. Yoshikawa T, Tainaka K, Naito Y, Kondo M. A novel cancer therapy based on oxygen radicls. Cancer Res 1995; 55: 1617-1620.
76. Chen Q, Espey MG, Krishna MC, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a prodrug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 2005; 102: 13604-13609.
77. Rahman A, Shahab Udddin A, Hadi SM, Parish JM. Complexes involving quercetin, DNA, and Cu(II). Carcinogenesis 1990; 11: 2001-2003.
78. Ehrenfeld GM, Shipley JB, Heimbrook DC, et al. Copper dependent cleavage of DNA by bleomycin. Biochemistry 1987; 26: 931-942.
79. Saikagami H, Satoh K. Modulating factors of radical intensity and cytotoxic action of ascorbate. Anticancer Res 1997; 17: 3513-3520.
80. Wang Y, Ness BR. Site-specific cleavage of supercoiled DNA by ascorbate/Cu(II). Nucleic Acid Res 1989; 17: 6915-6926.
81. Zimmer C, Luck G, Fritzsche H, Triebel H. DNA-Copper (II) complex and the DNA conformation. Biopolymers 1971; 10: 441-463.
82. Hadi SM, Ullah MF, Shamim U, Bhat SH, Azmi AS. Catalytic therapy of cancer by ascorbate involves redox cycling of endogenous/ exogenous copper and generation of reactive oxygen species. Chemotherapy 2010; 56: 280-284.
83. Ullah MF, Khan HY, Zubair H, Shamim U, Hadi SM. The antioxidant ascorbic acid mobilizes nuclear copper leading to a prooxidant cellular DNA breakage: Implications for chemopreventive action against cancer. Cancer Chemother pharmacol 2011; 67: 103-110.
84. Pryor WA. Why is hydroxyl radical the only radical that commonly binds to DNA? Hypothesis: it has rare combination of high electrophilicity, thermochemical reactivity and a mode of production near DNA. Free Rad Biol Med 1988; 4: 219-233.
85. Sakagami H, Satoh K, Hakeda Y, Kumegawa M. Apoptosis- inducing activity of vitamin C and vitamin K. Cell Mol Biol 2000; 46: 129-143.
86. Burkitt MJ, Milne L, Nicotera P, Orrenius S. 1, 10-Phenanthroline stimulates internucleosomal DNA fragmentation in isolated rat liver nuclei by promoting redox activity of endogenous copper ions. Biochem J 1996; 313: 163-169.
87. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007; 117: 1137-1146.
88. Goetzl EJ, Wasserman SI, Gigli I, et al. Enhancement of random migration and chemotactic response of human leukocytes by ascorbic acid. J Clin Invest 1974; 53: 813-818.
89. Manzella JP, Roberts NJ. Human macrophage and lymphocyte responses to mitogen stimulation after exposure to influenza virus, ascorbic acid, and hyperthermia. J Immunol 1979; 123: 1940-1944
90. Siegel BV. Enhancement of interferon production by poly(rI). poly(rC) in mouse cell cultures by ascorbic acid. Nature 1975; 254: 531-532.
91. Harakeh S, Jariwalla RJ, Pauling L Suppression of human immunodeficiency virus replication by ascorbate in chronically and acutely infected cells. Proc Natl Acad Sci USA 1990; 87: 7245-7249.
92. Aristo Vojdani, Mamdooh Ghoneum. In vivo effect of ascorbic acid on enhancement of human natural killer cell activity. Nutr Res 1993; 753-764.
93. Polterauer S, Grimm C, Seebacher V, et al. Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. Oncologist 2009; 14: 979-985.
94. Zhu WL, Fan BL, Liu DL, Zhu WX. Abnormal expression of fibrinogen gamma (FGG) and plasma level of fibrinogen in patients with hepatocellular carcinoma. Anticancer Res 2009; 29: 2531-2534.
95. Kanz R, Vukovich T, Vormittag R, et al. Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost 2011; 9: 57-63.
96. Wang CS, Sun CF. C-reactive protein and malignancy: clinicopathological association and therapeutic implication. Chang Gung Med J 2009; 32: 471-482.
97. Blay JY, Negrier S, Combaret V, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992; 52: 3317-3322.
98. Mayland C, Allen KR, Degg TJ, Bennet M. Micronutrient concentrations in patients with malignant disease: effect of the inflammatory response. Ann Clin Biochem 2004; 41: 138-141.
99. Block G, Jensen CD, Dalvi TB, et al. Vitamin C treatment reduces elevated C-reactive protein. Free Radic Biol Med 2009; 46: 70-77.
100. Lin ZY, Chuang WL. Pharmacologic concentrations of ascorbic acid cause diverse influence on differential expressions of angiogenic chemokine genes in different hepatocellular carcinoma cell lines. Biomed Pharmacother 2010; 64: 348-351.
101. Bowie AG, O'Neill LAJ. Vitamin C inhibits NF-kB activation by TNF via the activation of p38 mitogen-activated protein kinase. J Immunol 2000; 165: 7180-7388.
102. Burke MD, Thompson S, Elcombe CR, Halpert J, Haaparanta T, Mayer RT. Ethoxy-penthoxy and benzyloxyphexazones and homologues: A series of substrates to different induced cytochromes P450. Biochem Pharmacol 1985; 34: 3337-3345.
103. Wang YP, Yan J, Fu PP, Chou MW. Human liver microsomal reduction of pyrrolizidine alkaloid N-oxides to form the corresponding carcinogenic parent alkaloid. Toxicol Lett 2005; 155: 411-420.
104. Andrade R, Reyes FGR, Rath SA. A method for determination of volatile N-nitrosamines in food by HS-SPME-GC-TEA. Food Chem Toxicol 2005; 91: 173-179.
105. Yang CS, Smith T, Ishizaki H, Hong JY. Enzyme mechanism in the metabolism of nitrosamines. In: O'Neill, I.K., Chen, J., Bartsh, H. (Eds.), Relevance to Human Cancer of Nitroso Compounds, Tobacco Smoke and Mycotoxins. International Agency for Research on Cancer (IARC), 1991;Lyon, pp. 567-573.
106. Wong HL, Murphy SE, Hecht SS. Comparative metabolism of Nnitrosopiperidine and N nitrosopyrrolidine by rat liver and esophageal microsomes and cythocrome P450 2A3. Carcinogenesis 2003; 24: 291-300.
107. Fujita K, Kamataki T. Screening of organosulfur compounds as inhibitors of human CYP2A6. Drug Metabol Dispos 2001; 29: 983-989.
108. Arranz N, Haza AI, Garcia A, Rafter J, Morales P. Protective effect of vitamin C towards N-nitrosamine-induced DNA damage in the single-cell gel electrophoresis (SCGE)/HepG2 assay. Toxicol in vitro 2007; 21: 1311-137.
109. Kim JE, Sheen YY. Inhibition of 2,3,7,8-tetrachlorodibenzo-pdioxin (TCDD)-stimulated Cyp1a1 promoter activity by hypoxic agents. Biochem Pharmacol 2000; 59: 1549-1556.
110. Huff J, Lucier G, Tritscher A. Carcinogenicity of TCDD: experimental, mechanistic and epidermiology evidence. Ann Rev Pharmacol Toxicol 1994; 34: 343-372.
111. IARC (International Agency for Research on Cancer) Monographs on the evaluation of carcinogenesis risks humans. Polychlorinated Dibenzo-p-dioxins and Polychlorinated dibenzofurans. IARC Scientific Publication 69, 1997;Lyon France, pp. 1-631.
112. Chang HJ, Park JS, Lee EK, et al. Ascorbic acid suppresses the 2,3,7,8-tetrachloridibenxo-p-dioxin (TCDD)-induced CYP1A1 expression in human HepG2 cells. Toxicol in vitro 2009; 23: 622-626.
113. Gamet-Payrastre L, Li P, Lumeau S, et al. Sulphorane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res 2000; 60: 1426-1433.
114. Wang W, Higuchi CM. Induction of NAD(P)H: q uinine reductase by vitamins A, E and C in Colo205 colon cancer cells. Cancer Lett 1995; 98: 63-69.
115. Roomi MW, Netke S, Tsao C. Modulation of drug metabolizing enzymes in guinea pig liver by high intakes of ascorbic acid. Internat J Vit Nutr Res 1998; 68: 42-47.
116. Nigam VN, Cantero A. Polysaccharides in cancer: glycoproteins and glycolipids. Adv. Cancer Res 1973; 17: 1-80.
117. Steven FS, Knott J, Jackson DS, Podrazky V. Collagen proteinpolysaccharide interactions in human intervertebral disc. Biochim Biophys Acta 1969; 188: 307-13.
118. Trosko JE. Commentary: is the concept of "tumor promotion" a useful paradigm? Mol Carcinog 2001; 30: 131-137.
119. Trosko JE, Chang CC. Modulation of cell-cell communication in the cause and chemoprevention/chemotherapy of cancer. Biofactors 2000; 12: 259-263.
120. Rosenkranz HS, Pollack N, Cunningham AR. Exploring the relationship between the inhibition of gap junctional intercellular communication and other biological phenomena. Carcinogenesis 2000; 21: 1007-1011.
121. Lee KW, Lee HJ, Kang KS, Lee CY. Preventive effects of vitamin C on carcinogenesis. Lancet 2002; 359: 172
122. Ki Won Lee, Hyong Joo Lee, Young-Joon Surh, Chang Yong Lee. Vitamin C and cancer chemoprevention: reappraisal. Am J Clin Nutr 2003; 78: 1074-1078.
123. Banks WA, Kastin AJ: Peptides and blood brain barrier: lipophilicity as predictor of permeability. Brain Res Bull 1985; 15: 287-292.
124. Naidu KA, Tang JL, Naidu KA, Prockop LD, Nicosia SV, Coppola D. Antiproliferative and apoptotic effect of ascorbyl stearate in human glioblastoma multiforme cell: Modulation of insulin- like growth factor-I receptor (IGF-IR) expression. J Neuro- Oncol 2001; 54: 15-22.
125. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, et al. AKT2 a putative oncogene encoding a member of a subfamily of proteinserine/ threonine kinase is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 1992; 89: 9267-9271.
126. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2; amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 1987; 84: 5034-5037.
127. Fang Q, Naidu KA, Naidu KA, et al. Ascorbyl Stearate Inhibits Cell Proliferation and Tumor Growth in Human Ovarian Carcinoma Cells by Targeting the PI3K/AKT Pathway. Anticancer Res 2006; 26: 203-210.
128. Ha YM, Park MK, Kim HJ, Seo HG, Lee JH, Chang KC. High concentrations of ascorbic acid induces apoptosis of human gastric cancer cell by p38-MAP kinase-dependent up-regulation of transferrin receptor. Cancer Lett 2009; 277: 48-54.
129. Rankin E, Giaccia A. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008; 15: 678-685.
130. Verrax J, Calderon BP. The controversial place of vitamin C in cancer treatment. Biochem Pharmacol 2008; 76; 1644-1652.
131. Semenza G. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-32.
132. Li L, Lin X, Staver M, Shoemaker A, et al. Evaluating hypoxiainducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 2005; 65: 7249-7258.
133. Page E, Chan D, Giaccia A, Levine M, Richard D. Hypoxiainducible factor-1{alpha} stabilization in nonhypoxic conditions: role of oxidation and intracellular ascorbate depletion. Mol Biol Cell 2008; 19: 86-94.
134. Vissers M, Gunningham S, Morrison M, Dachs G, Currie M. Modulation of hypoxia-inducible factor-1 alpha in cultured primary cells by intracellular ascorbate. Free Radic Biol Med 2007; 42: 765-772.
135. Cameron E, Campbell A. The ortho molecular treatment of cancer II. Clinical trial of high-dose ascorbic supplements in advanced human cancers. Chem Biol Interact 1974; 9: 285-315.
136. Cameron E, Pauling L Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancers. Proc Natl Acad Sci USA 1978; 75: 4538-4542.
137. Morishige F, Murata A. Prolongation of survival times in terminal human cancer by administration of supplemental ascorbate. J Interntl Acad Prev Med 1979; 5: 47-52.
138. Murata A, Morishige F, Yamaguchi H. Prolongation of survival times of terminal cancer patients by administration of large doses of ascorbate. Int J Vitam Nutr Res Suppl 1982; 23: 103-113.
139. Rozanova N, Zhang JZ, and Heck DE. Catalytic therapy of cancer with ascorbate and extracts of medicinal herbs. Evid Based Complement Alternat Med 2007; 7: 203-212.
140. Kimoto EH, Tanaka K, Gytoku P, Morishige F, Pauling L. Enhancement of anti-tumor activity of ascorbate against Ehrlich ascites tumor cells by copper:glycylglycyl complex. Cancer Res 1983; 43: 824-828.
141. Aidoo A, Lyn-Cook LE, Lensing S, Wamer W. Ascorbic acid (vitamin C) modulates the mutagenic effects produced by an alkylating agent in vivo. Environ Mol Mutagen 1994; 24: 220-228.
142. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J, Levine M Pharmacologic doses of ascorbate act as a prooxidant and decrease growth aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 2008; 105: 11105-1109
143. Ping Chen, Jennifer Stone, Garrett Sullivan, Jeanne A. Drisko, Qi Chen. Anti-cancer effect of pharmacologic ascorbate and its interaction with supplementary parenteral glutathione in preclinical cancer models. Free Rad Biol Med 2011; 51: 681-687.
144. Biswas S, Ray M, Misra S, Dutta DP, Ray S. Selective inhibition of mitochondrial respiration and glycolysis in human leukemic leukocytes by methylglyoxal. Biochem J 1997; 323: 343-348.
145. Ghosh M, Talukdar D, Ghosh S, Bhattacharyya N, Ray M, Ray S. In vivo assessment of toxicity and pharmacokinetics of methylglyoxal Augmentation of the curative effect of methylglyoxal on cancer-bearing mice by ascorbic acid and creatine. Toxicol Appl Pharmacol 2006; 212: 45-58.
146. Prasad K, Sinha P, Ramanujam M, Sakamoto A. Sodium ascorbate potentiates the growth inhibitory effect of certain agents on neuroblastoma cells in culture. Proc Natl Acad Sci USA 1979; 76: 829-832.
147. Kassouf W, Highshaw R, Nelkin G, Dinney C, Kamat A. Vitamins C, K sensitize human urothelial tumors to gemcitabine. J Urol 2006; 176: 1642-1647.
148. Kurbacher C, Wagner U, Kolster B, Andreotti P, Krebs D, Bruckner H. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett 1996; 103: 183-19.
149. Taper H, Keyeux A, Roberfroid M. Potentiation of radiotherapy by nontoxic pretreatment with combined vitamins C and K3 in mice bearing solid transplantable tumor. Anticancer Res 1996; 16: 499-503.
150. Taper H, de Gerlache J, Lans M, Roberfroid M. Non-toxic potentiation of cancer chemotherapy by combined C and K3 vitamin pretreatment. Int J Cancer 1987; 40: 575-579.
151. Reddy V, Khanna N, Singh N, Vitamin. C augments chemotherapeutic response of cervical carcinoma HeLa cells by stabilizing P53. Biochem Biophys Res Commun 2001; 282: 409-415.
152. Chiang C, Song E, Yang V, Chao C. Ascorbic acid increases drug accumulation and reverses vincristine resistance of human nonsmall- cell lung-cancer cells. Biochem J 1994; 301: 759-764.
153. Song E, Yang V, Chiang C, Chao C. Potentiation of growth inhibition due to vincristine by ascorbic acid in a resistant human nonsmall cell lung cancer cell line. Eur J Pharmacol 1995; 292: 119-125.
154. Bahlis N, McCafferty-Grad J, Jordan-McMurry I, et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acidmediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 2002; 8: 3658-3668.
155. Grad J, Bahlis N, Reis I, Oshiro M, Dalton W, Boise L. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001; 98: 805-813.
156. Dai J, Weinberg R, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93: 268-277.
157. Karasavvas N, Cárcamo J, Stratis G, Golde D. Vitamin C protects HL60 and U266 cells from arsenic toxicity. Blood 2005; 105: 4004-4012.
158. Perez-Cruz I, Cárcamo J, Golde D. Caspase-8 dependent TRAILinduced apoptosis in cancer cell lines is inhibited by vitamin C and catalase. Apoptosis 2007; 12: 225-234.
159. Zou W, Yue P, Lin N, He M, Zhou Z, Lonial S, et al. Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res 2006; 12: 273-280.
160. Kim JE, Cho HS, Yang HS, et al. Depletion of ascorbic acid impairs NK cell activity against ovarian cancer in a mouse model. Immunobiol 2012; 217: 873-881.
161. Wright ME, Andreotti G, Lissowska J, et al. Genetic variation in sodium-dependent ascorbic acid transporters and risk of gastric cancer in Poland. Eur J Cancer 2009; 45: 1824-1830.
162. Schorah CJ, Sobala GM, Sanderson M, Collis N, Primrose JN. Gastric juice ascorbic acid: effects of disease and implications for gastric carcinogenesis. Am J Clin Nutr 1991; 53: 287S-293S.
163. Cameron E, Campbel A, Jack T. The orthomolecular treatment of cancer: III. Reticulum cell sarcoma: Double complete regression induced by high-dose ascorbic acid therapy. Chemico-Biol Interact 1975; 11: 387-393.
164. Riordan HD, Jackson JA, Schultz M: Case Study: High-dose intravenous vitamin C in the treatment of a patient with adenocarcinoma of the kidney. J Orthomol Med 1990; 5: 5-7.
165. Sebastian J. Padayatty, Hugh D, et al. Intravenously administered vitamin C as cancer therapy: three cases. CMAJ 2006; 174: 937-942.
166. Levine M, Dhariwal KR, Washko PW, et al. Ascorbic acid and in situ kinetics: a new approach to vitamin requirements. Am J Clin Nutr 1991; 54: 1157S-1162S.
167. Yeom CH, Lee G, Park JH, Yu J, Park S, et al. High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/Cmice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis. J Transl Med 2009; 7: 70-74.
168. Verrax J, Calderon PB. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med 2009; 47: 32-40.
169. Montil DA, Mitchell E, Bazzan AJ, et al. Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer. PLOS ONE 2012; 7: e29794.
170. Espey MG, Chen P, Chalmers B, Drisko J, Sun AY, et al. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med 2011; 50: 1610-1619.
171. Berenson JR, Yellin O, Woytowitz D, et al. Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen. Eur J Haematol 2009; 82: 433-49.
172. Suhail N, Bilal N, Khan HY, et al. Effect of vitamins C and E on antioxidant status of breast-cancer patients undergoing chemotherapy. J Clin Pharm Ther 2012; 37: 22-26.